2nd Next Gen Inhalation Delivery Summit

In an era marked by remarkable advancements, the inhalation therapy field is rapidly evolving. From Avalyn's $175 million investment in inhaled pulmonary fibrosis trials to Krystal Biotech's FDA clearance for inhaled gene therapy and MIT engineers' work on inhaled nanoparticles, the field is abuzz with new advances and breakthroughs in inhalation delivery.

Right now, we explore inhaled therapies as an opportunity to re-purpose modalities to tackle unmet clinical need in diseases like COPD, asthma, IPF, emphysema, and lung cancer, to unlock therapeutic efficacy. Now is the time for the industry to unite and innovate solutions to challenges surrounding particle engineering, stability, and formulation-device compatibility. Immerse yourself in a wealth of knowledge at the 2nd Next Gen Inhalation Delivery Summit, as the only forum offering cutting edge, future focused updates for inhaled delivery of complex biologics, maintaining formulation integrity to achieve precise lung delivery.

This is the premier forum dedicated to inhalation's future, providing crucial insights and networking opportunities. Join us in June to stay ahead in optimizing lung-specific drug delivery for maximum efficacy and potency in non-invasive, localized delivery.

URL:
Brochure: https://go.evvnt.com/2262398-0?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Conference + 2 Pre-Conference Workshops - Industry Pricing: USD 4197.00,
Conference + 1 Pre-Conference Workshop - Industry Pricing: USD 2698.00,
Conference Only - Industry Pricing: USD 2299.00,
Conference + 2 Pre-Conference Workshops - Academic Pricing: USD 3597.00,
Conference + 1 Pre-Conference Workshop - Academic Pricing: USD 3098.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + 2 Pre-Conference Workshops - Solution Provider Pricing: USD 5097.00,
Conference + 1 Pre-Conference Workshop - Solution Provider Pricing: USD 4398.00,
Conference Only - Solution Provider Pricing : USD 3699.00

Speakers: Anna Cheng, Director - R and D Pulmonary Drug Delivery, Feldan Therapeutics , Colin Scott, CEO, Highland Airs Consultancy, Jaap Wieling, CEO, PureIMS, Joshua Ziel, Chief Operating Officer, Aerami Therapeutics, Jyothi Menon, Assistant Professor, University of Rhode Island, Mariam Ibrahim, Senior Scientist, AstraZeneca, Michael Tauber, Senior Director - Pharmaceutical Development, Acorda Therapeutics, Nitesh Kunda, Assistant Professor, st johns university, Philippe Rogueda, Director and Co-Founder, Anthocan, Ronan Mac Loughlin ,Associate Director - Research, Development, Science and Emerging Technologies, Aerogen, Samiran De, Director, Product Development , Avalyn Pharma, Simone Carneiro, Postdoctoral Fellow, Ludwig Maximilians University Munich, Tony Zhou, Associate Professor, Purdue University, Vivek Lal, Founder, Executive Chairman and Chief Scientific Officer, Alveolus Bio, Wayne Buck, Investigative Toxicology and Pathology, Abbvie